{"id":"amorolfine-antifungal","safety":{"commonSideEffects":[{"rate":null,"effect":"Local irritation at application site"},{"rate":null,"effect":"Burning or stinging sensation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL489411","moleculeType":"Small molecule","molecularWeight":"317.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amorolfine is a morpholine antifungal that selectively inhibits the cytochrome P450-dependent enzyme lanosterol 14α-demethylase in fungi. This blocks the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. The resulting depletion of ergosterol and accumulation of toxic sterol precursors leads to cell membrane dysfunction and fungal cell death.","oneSentence":"Amorolfine inhibits fungal sterol synthesis by blocking lanosterol demethylase, disrupting the integrity of the fungal cell membrane.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:10.979Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Onychomycosis (fungal nail infection)"},{"name":"Dermatophyte and non-dermatophyte fungal infections of the skin"}]},"trialDetails":[{"nctId":"NCT05482763","phase":"","title":"Mycosis Culture Collection From Dermatological Isolated","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Rome Tor Vergata","startDate":"2022-07-20","conditions":"Onychomycosis, Resistant Infection, Nail Diseases","enrollment":200},{"nctId":"NCT01014637","phase":"PHASE4","title":"Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis","status":"UNKNOWN","sponsor":"Pierre Fabre Dermo Cosmetique","startDate":"2009-08","conditions":"Onychomycosis","enrollment":260}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":210,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Loceryl"],"phase":"marketed","status":"active","brandName":"Amorolfine (Antifungal)","genericName":"Amorolfine (Antifungal)","companyName":"Pierre Fabre Dermo Cosmetique","companyId":"pierre-fabre-dermo-cosmetique","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amorolfine inhibits fungal sterol synthesis by blocking lanosterol demethylase, disrupting the integrity of the fungal cell membrane. Used for Onychomycosis (fungal nail infection), Dermatophyte and non-dermatophyte fungal infections of the skin.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}